Previous 10 | Next 10 |
SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution (“Plan of Dissolution”) that would include the d...
2023-07-05 16:14:06 ET Therapeutics company Histogen ( NASDAQ: HSTO ) said on Monday that it has completed a review of its business, and plans to commence a process to explore strategic alternatives. The potential strategic alternatives may include an acquisition, merger, reve...
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to re...
2023-05-11 16:57:29 ET Histogen press release ( NASDAQ: HSTO ): Q1 GAAP EPS of -$0.81. Revenues for the three months ended March 31, 2023 and 2022, we recognized license revenue of $5 thousand and $3.8 million, respectively. Research and development expenses for t...
Received FDA Clearance of IND Application for Emricasan for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Signed Exclusive Intellectual Property License Agreement w...
Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO), a clinical-stage ther...
2023-04-03 17:18:03 ET Histogen ( NASDAQ: HSTO ) on Monday said it had signed an exclusive license agreement with Johns Hopkins University, sending its shares about 5% higher to $1.25 after hours. "The intellectual property associated with this license covers the use of em...
Licensed Patents Expected to Provide Freedom to Operate and Exclusivity for Emricasan Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, April 03, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO), a clinical-stage therapeu...
2023-03-20 06:00:00 ET 3 Sectors to Find Penny Stocks That Could Be Worth Buying Navigating the vast landscape of penny stocks can be an exciting venture for investors looking to capitalize on hidden gems. Although these stocks are often seen as risky due to their low price, they can of...
2023-03-18 06:00:00 ET 3 Tips for Making Money With Penny Stocks in 2023 As an investor looking to succeed with penny stocks , it’s essential to develop a winning mindset that will enable you to make the most out of small-cap investments in 2023. One of the keys to success in...
News, Short Squeeze, Breakout and More Instantly...
Histogen Inc. Company Name:
HSTO Stock Symbol:
NASDAQ Market:
JD.com Inc. (JD) is expected to report $0.56 for Q1 2024 Volkswagen AG (VLKAF) is expected to report for Q1 2024 CalAmp Corp. (CAMP) is expected to report for Q4 2024 Sonic Foundry Inc. (SOFO) is expected to report for Q2 2024 Moatable Inc ADR (R2RS:MU) is expected to report for Q...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO, the “Company” or “Histogen”), a drug development company for treatment of bacterial skin infections, today announced that it has filed voluntary petitions for relief under subchapter V of Chapter 11 of ...